Molecure S.A. (WSE: MOC) is a clinical-stage Polish biotechnology firm focused on small molecule therapies targeting unexplored protein and RNA targets. With a proprietary discovery engine and strategic partnerships, including with global pharma, Molecure is advancing programs in oncology, immunology, and respiratory diseases. The company combines internal R&D with open innovation to accelerate drug development. It offers investors high-risk, high-reward exposure to first-in-class therapeutics emerging from European biotech research.
Últimos artículos sobre acciones